Los Angeles, June 3, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA)....

Los Angeles, May 21, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board.  Dr. Greenberg will...

Los Angeles, April 22, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summit...

Los Angeles, March 31, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lou...

Los Angeles, February 25, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced research results in the peer-reviewed journal Immunology demonstrating that TRE-515 selectively...